|
Gene: CELF1 |
Gene summary for CELF1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CELF1 | Gene ID | 10658 |
Gene name | CUGBP Elav-like family member 1 | |
Gene Alias | BRUNOL2 | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92879 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10658 | CELF1 | CA_HPV_1 | Human | Cervix | CC | 4.85e-02 | -6.74e-02 | 0.0264 |
10658 | CELF1 | CCI_2 | Human | Cervix | CC | 1.73e-06 | 6.72e-01 | 0.5249 |
10658 | CELF1 | CCI_3 | Human | Cervix | CC | 1.68e-03 | 6.04e-01 | 0.516 |
10658 | CELF1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.06e-08 | 5.49e-01 | -0.1954 |
10658 | CELF1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.45e-03 | 4.50e-01 | 0.294 |
10658 | CELF1 | F007 | Human | Colorectum | FAP | 6.35e-05 | -3.80e-01 | 0.1176 |
10658 | CELF1 | A002-C-010 | Human | Colorectum | FAP | 1.01e-04 | -2.11e-01 | 0.242 |
10658 | CELF1 | A001-C-207 | Human | Colorectum | FAP | 2.15e-02 | -1.16e-01 | 0.1278 |
10658 | CELF1 | A015-C-203 | Human | Colorectum | FAP | 7.33e-35 | -4.06e-01 | -0.1294 |
10658 | CELF1 | A015-C-204 | Human | Colorectum | FAP | 1.69e-09 | -3.37e-01 | -0.0228 |
10658 | CELF1 | A014-C-040 | Human | Colorectum | FAP | 2.48e-07 | -4.27e-01 | -0.1184 |
10658 | CELF1 | A002-C-201 | Human | Colorectum | FAP | 6.13e-15 | -3.32e-01 | 0.0324 |
10658 | CELF1 | A002-C-203 | Human | Colorectum | FAP | 1.19e-04 | -7.60e-02 | 0.2786 |
10658 | CELF1 | A001-C-119 | Human | Colorectum | FAP | 2.22e-09 | -3.96e-01 | -0.1557 |
10658 | CELF1 | A001-C-108 | Human | Colorectum | FAP | 1.68e-19 | -3.26e-01 | -0.0272 |
10658 | CELF1 | A002-C-205 | Human | Colorectum | FAP | 2.92e-31 | -5.17e-01 | -0.1236 |
10658 | CELF1 | A001-C-104 | Human | Colorectum | FAP | 2.25e-06 | -3.20e-01 | 0.0184 |
10658 | CELF1 | A015-C-005 | Human | Colorectum | FAP | 1.21e-02 | -1.33e-01 | -0.0336 |
10658 | CELF1 | A015-C-006 | Human | Colorectum | FAP | 3.34e-20 | -3.42e-01 | -0.0994 |
10658 | CELF1 | A015-C-106 | Human | Colorectum | FAP | 1.81e-17 | -3.46e-01 | -0.0511 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064174 | Colorectum | FAP | regulation of translation | 111/2622 | 468/18723 | 8.47e-09 | 1.13e-06 | 111 |
GO:00003774 | Colorectum | FAP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 83/2622 | 320/18723 | 9.66e-09 | 1.23e-06 | 83 |
GO:00003984 | Colorectum | FAP | mRNA splicing, via spliceosome | 83/2622 | 320/18723 | 9.66e-09 | 1.23e-06 | 83 |
GO:00434884 | Colorectum | FAP | regulation of mRNA stability | 50/2622 | 158/18723 | 1.01e-08 | 1.27e-06 | 50 |
GO:00003804 | Colorectum | FAP | alternative mRNA splicing, via spliceosome | 29/2622 | 77/18723 | 2.07e-07 | 1.24e-05 | 29 |
GO:00459273 | Colorectum | FAP | positive regulation of growth | 66/2622 | 259/18723 | 6.11e-07 | 3.05e-05 | 66 |
GO:00442704 | Colorectum | FAP | cellular nitrogen compound catabolic process | 101/2622 | 451/18723 | 7.42e-07 | 3.44e-05 | 101 |
GO:00718264 | Colorectum | FAP | ribonucleoprotein complex subunit organization | 59/2622 | 227/18723 | 1.18e-06 | 5.26e-05 | 59 |
GO:00346554 | Colorectum | FAP | nucleobase-containing compound catabolic process | 92/2622 | 407/18723 | 1.50e-06 | 6.49e-05 | 92 |
GO:00226184 | Colorectum | FAP | ribonucleoprotein complex assembly | 57/2622 | 220/18723 | 1.99e-06 | 8.03e-05 | 57 |
GO:00467004 | Colorectum | FAP | heterocycle catabolic process | 98/2622 | 445/18723 | 2.36e-06 | 9.21e-05 | 98 |
GO:00003814 | Colorectum | FAP | regulation of alternative mRNA splicing, via spliceosome | 23/2622 | 60/18723 | 2.58e-06 | 9.88e-05 | 23 |
GO:19033132 | Colorectum | FAP | positive regulation of mRNA metabolic process | 36/2622 | 118/18723 | 2.94e-06 | 1.09e-04 | 36 |
GO:00486392 | Colorectum | FAP | positive regulation of developmental growth | 47/2622 | 174/18723 | 4.55e-06 | 1.52e-04 | 47 |
GO:00194394 | Colorectum | FAP | aromatic compound catabolic process | 100/2622 | 467/18723 | 6.75e-06 | 2.08e-04 | 100 |
GO:00486382 | Colorectum | FAP | regulation of developmental growth | 75/2622 | 330/18723 | 1.11e-05 | 3.10e-04 | 75 |
GO:00610142 | Colorectum | FAP | positive regulation of mRNA catabolic process | 27/2622 | 87/18723 | 3.50e-05 | 7.69e-04 | 27 |
GO:19013614 | Colorectum | FAP | organic cyclic compound catabolic process | 101/2622 | 495/18723 | 4.87e-05 | 9.93e-04 | 101 |
GO:00611572 | Colorectum | FAP | mRNA destabilization | 25/2622 | 84/18723 | 1.43e-04 | 2.24e-03 | 25 |
GO:00507792 | Colorectum | FAP | RNA destabilization | 25/2622 | 88/18723 | 3.19e-04 | 4.12e-03 | 25 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CELF1 | SNV | Missense_Mutation | novel | c.1075N>A | p.Gly359Ser | p.G359S | protein_coding | tolerated(0.28) | benign(0) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
CELF1 | SNV | Missense_Mutation | c.432N>C | p.Lys144Asn | p.K144N | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
CELF1 | SNV | Missense_Mutation | novel | c.1475N>A | p.Gly492Asp | p.G492D | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
CELF1 | SNV | Missense_Mutation | rs746684771 | c.470C>T | p.Ser157Leu | p.S157L | protein_coding | deleterious(0.02) | benign(0.257) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
CELF1 | SNV | Missense_Mutation | c.976G>T | p.Gly326Trp | p.G326W | protein_coding | deleterious(0.03) | probably_damaging(0.977) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CELF1 | SNV | Missense_Mutation | c.1058N>T | p.Thr353Met | p.T353M | protein_coding | tolerated(0.07) | possibly_damaging(0.458) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
CELF1 | SNV | Missense_Mutation | c.563N>T | p.Ala188Val | p.A188V | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | ||
CELF1 | SNV | Missense_Mutation | c.509N>A | p.Pro170His | p.P170H | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
CELF1 | SNV | Missense_Mutation | novel | c.1414N>G | p.Phe472Val | p.F472V | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CELF1 | SNV | Missense_Mutation | novel | c.952N>A | p.Leu318Ile | p.L318I | protein_coding | tolerated(0.35) | probably_damaging(0.953) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |